Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB

Figure 1 Change in methylation state of RASSF1A gene in gastric cancer cell line SGC7901. Markers: DL2000; 1-7: Control, 5-Aza-CdR at 1.0 &mgr;mol/L, 5-Aza-CdR at 3.0 &mgr;mol/L, NaB at 1.0 mmol/L, NaB at 3.0 mmol/L, 5-Aza-CdR at 1.0 &mgr;mol/L in combination with NaB at 1.0 mmol/L, and 5-Aza-CdR at 3.0 &mgr;mol/L in combination with NaB at 3.0 mmol/L; P: Positive control; M: Methylated result; U: Un-methylated result; 1, 4 and 5: Methylation positive, 94 bp; 2, 3, 6 and 7: Methylation negative, 108 bp.

Figure 2 A: Change of mRNA expression of RASSF1A gene in gastric cancer cell lines SGC7901 and BGC823. Markers: DL2000; 1-7 and 8-14: Control, 5-Aza-CdR at 1.0 &mgr;mol/L, 5-Aza-CdR at 3.0 &mgr;mol/L, NaB at 1.0 mmol/L, NaB at 3.0 mmol/L, 5-Aza-CdR at 1.0 &mgr;mol/L in combination with NaB at 1.0 mmol/L, and 5-Aza-CdR at 3.0 &mgr;mol/L in combination with NaB at 3.0 mmol/L of SGC7901 and BGC823 respectively; P: Positive control, 330 bp; B: mRNA expression of β-actin in gastric cancer cell lines SGC7901 and BGC823.

Figure 3 A: Change of protein expression of RASSF1A gene in gastric cancer cell line SGC7901; B: Change of protein expression of RASSF1A gene in gastric cancer cell line BGC823. 1-7: Control, 5-Aza-CdR at 1.0 &mgr;mol/L, 5-Aza-CdR at 3.0 &mgr;mol/L, NaB at 1.0 mmol/L, NaB at 3.0 mmol/L, 5-Aza-CdR at 1.0 &mgr;mol/L in combination with NaB at 1.0 mmol/L, and 5-Aza-CdR at 3.0 &mgr;mol/L in combination with NaB at 3.0 mmol/L; P: Positive control, 39 kDa.